Teligent Inc., a Buena-based speciality generic pharmaceutical company, announced on Monday that John Celentano has been appointed chairman of its board of directors.
Celentano, who’s been an independent director of Teligent since March 2015, will be replacing James C. Gale who opted not to stand for reelection to focus on other business interests. He will also continue to serve as a member of Teligent’s Compensation and Audit Committees.
Prior to Teligent, Celentano held senior leadership roles at Bristol-Myers Squibb, including president, Bristol-Myers Squibb Healthcare Group; regional president in Emerging Markets/Asia Pacific, Latin America/Canada and UK/Northern Europe; senior vice president of human resources, public affairs and philanthropy; and senior vice president of strategy and productivity.
“We are excited to leverage John’s broad, extensive experience in the pharmaceutical industry and proven boardroom leadership in the role of chairman of Teligent’s board of directors,” Timothy B. Sawyer, CEO and president of Teligent, said. “We look forward to working closely with John as our new chairman and the board joins me in thanking Jim Gale for his service and wishing him well as he focuses on his private endeavors.”